On October 12, 2022 CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, reported that it will take part in two upcoming investor conferences (Press release, CANbridge Life Sciences, OCT 12, 2022, View Source [SID1234621972]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Jefferies London Healthcare Conference, November 15-17
The Morgan Stanley 21st Annual Asia Pacific Summit, Singapore, November 16-18
The company’s presentation will be available on the website in the Investor section.
In addition, the company announced that data from a pre-clinical development program in collaboration with UMass Chan Medical School will be presented at:
The ESGCT 29th Congress, in Edinburgh, Scotland, October 13, 3:30 PM BST
Title: Endogenous Human SMN1 Promoter-driven Gene Replacement Improves the Efficacy and Safety of AAV9-mediated Gene Therapy for Spinal Muscular Atrophy in Mice
Type: Oral presentation
Presenter: Guangping Gao, Ph.D., Co-Director, Li Weibo Institute for Rare Diseases Research, Director, the Horae Gene Therapy Center and Viral Vector Core, Professor of Microbiology and Physiological Systems and Penelope Booth Rockwell Professor in Biomedical Research at UMass Chan Medical School